During the past 12 months, Lakefront Biotherapeutics NV's average Total Assets Growth Rate was -46.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -13.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 2.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 24.50% per year.
During the past 13 years, Lakefront Biotherapeutics NV's highest 3-Year average Total Assets Growth Rate was 165.10%. The lowest was -13.90%. And the median was 13.50%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Lakefront Biotherapeutics NV's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Lakefront Biotherapeutics NV Total Assets Related Terms
Lakefront Biotherapeutics NV Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (GLPGF) has a Total Assets of $3,899 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Total Assets too high?
Lakefront Biotherapeutics NV's current Total Assets is $3,899 Mil. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Total Assets compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Total Assets of $3,899 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Total Assets is $3,899 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (GLPGF) is currently considered Possible Value Trap. The stock's GF Value™ is $136.98, compared to a current price of $28.08 — trading 79.5% below its estimated fair value. The current Total Assets is $3,899 Mil. Lakefront Biotherapeutics NV's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current Total Assets is $3,899 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.08 is trading 79.5% below its estimated GF Value™ of $136.98.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for GLPGF:
Total Assets: $3,899 Mil
GF Value™: $136.98 vs. price of $28.08 (79.5% below fair value)
No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
62GF Score
Get the complete analysis for GLPGF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLPGF has been successfully added to your 
